Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - BIOVEST INTERNATIONAL INC | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 7, 2011
BIOVEST INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 00-11480 | 41-1412084 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
324 South Hyde Park Avenue, Suite 350
Tampa, FL 33606
(Address of Principal Executive Offices; Zip Code)
Registrant’s telephone number, including area code: (813) 864-2554
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
BIOVEST INTERNATIONAL, INC.
FORM 8-K
Item 7.01. Regulation FD Disclosure.
The following information is being furnished under Item 7.01 of Form 8-K, the Press Release dated March 7, 2011, by the Company, titled “Biovest is Awarded Orphan Drug Status for its Personalized Cancer Vaccine for the Treatment of Mantle Cell Lymphoma in European Union”. A copy of this press release is attached as Exhibit 99-1 to this Form 8-K
Item 9.01. Financial Statements and Exhibits.
See the Exhibit Index set forth below for a list of exhibits included with this Form 8-K.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized.
| BIOVEST INTERNATIONAL, INC. | ||
| By: | /s/ Samuel S. Duffey | |
| Samuel S. Duffey | ||
| President and General Counsel | ||
Date: March 7, 2011
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Press Release Dated March 7, 2011 titled “Biovest is Awarded Orphan Drug Status for its Personalized Cancer Vaccine for the Treatment of Mantle Cell Lymphoma in European Union”. | |